Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (Nasdaq: MSFT ) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases.
Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. Tevogen.AI's proprietary approach may overcome these challenges by:
'I'm pleased with Tevogen.AI's continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,' said Dr. Ryan Saadi, Founder and CEO of Tevogen. 'Leveraging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.'
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
4 minutes ago
- Fox News
Pro-life group 'elated' after Planned Parenthood shutters Houston facilities: 'Tremendous victory'
EXCLUSIVE: A pro-life group is celebrating a "tremendous victory" after Planned Parenthood announced two of its facilities in Houston, Texas, will be shutting down this fall, as Republican lawmakers continue to target the organization. In an exclusive interview with Fox News Digital, 40 Days for Life CEO and founder Shawn Carney, a Houston resident, expressed "both personal and professional elation" at the shuttering of the facilities, including the 78,000-square-foot clinic that he said was the largest abortion facility in the Western Hemisphere. "This is massive news for the pro-life movement and shows the direction that Planned Parenthood is going, which is down," Carney said. Planned Parenthood Gulf Coast — which runs six clinics in the Houston area and two in Louisiana — will close its Prevention Park and Southwest centers on Sept. 30, while the other Houston facilities will be acquired by the organization's largest Texas affiliate. This comes amid several closures of Planned Parenthood facilities in various states, including New York, where the organization is selling its only Manhattan health center building for $39 million. Facilities in GOP-led states with abortion restrictions, including Texas, have also been forced to cease procedures following the 2022 Supreme Court decision that overturned Roe V. Wade and sent decisions regarding abortion back to the states. "Now they are closing the largest abortion facility in the world," Carney said. "Their flagship. They're very proud of it in Houston, Texas. They're finally closing it, and it's unbelievable." The company cited rising costs, staffing shortages and low reimbursement rates as the reasons for closing the two Houston facilities. GOP officials in recent years have made repeated attempts to shut down Planned Parenthood, even after nearly all abortions were banned under Texas law. The Trump administration has sought to impose funding cuts to Planned Parenthood that could lead to the closure of additional facilities. A provision in a GOP-backed bill would end Medicaid payments for one year to abortion providers that received more than $800,000 from the program in 2023. A judge granted a preliminary injunction earlier this week blocking the government from cutting Medicaid payments to Planned Parenthood member organizations that either do not provide abortions or did not meet a threshold of at least $800,000 in Medicaid reimbursements in a given year. Carney said 40 Days for Life has prayed and held vigils outside the Houston mega-facility since 2006. "Countless people have gone out, offered alternatives. We've had pro-life buses outside to do free ultrasounds. There have been so many lives saved, but to be honest, it just seemed like they were Goliath and it didn't matter if we were David," he said, adding that the "behemoth" facility even provided late-term abortions at one point. "They were just going to always be open and always be victorious." Carney described the closing of the facilities as a "tremendous victory" for the pro-life movement and said it represents "one of the biggest victories that we've had" following the overturning of Roe v. Wade. "Planned Parenthood has always been very top-heavy in D.C., and that's been a weakness for the pro-life movement. But once [the court] sent it back to the states, it was sending it back to the place where the pro-life movement was the strongest, which was the grassroots," he said. The closure of the two Houston facilities shows "more than anything else" that "the pro-life movement is built for a post-Roe America," Carney said, adding that Planned Parenthood is not a "monster that can't go away." "They are very, very vulnerable. When you look at the New York closing and the Houston closing, this is what that represents. All the nonsense about other services and serving women and helping low-income women. Because when you take away abortions or you offer alternatives, they close, and they close their most prosperous locations," he said.
Yahoo
9 minutes ago
- Yahoo
GDEV Sends Cash Back to Investors with Special Payout
GDEV Inc. (NASDAQ:GDEV) is included among the 14 Stocks that Paid Special Dividends in 2025. A gaming enthusiast in front of a widescreen monitor, lost in the game. GDEV Inc. (NASDAQ:GDEV) is a gaming and entertainment holding company dedicated to expanding and developing its portfolio of game franchises across multiple genres and platforms. Through its subsidiaries— such as Nexters and Cubic Games— it aims to produce games that captivate and entertain millions of players over the long term. Its popular titles, including Hero Wars, Island Hoppers, and Pixel Gun 3D, have collectively surpassed 550 million downloads and generated $2.5 billion in global bookings. On February 21, GDEV Inc. (NASDAQ:GDEV) announced that its Board of Directors had approved a one-time special cash dividend of $3.31 per share. This payout represents roughly a 20% yield, based on the volume-weighted average share price over the previous 30 trading days. The special dividend, amounting to around $60 million in total, will be funded using profits the company has accumulated in recent years. It represents part of GDEV's total cash holdings, which stood at approximately $153 million as of the third quarter of 2024. While we acknowledge the potential of GDEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
9 minutes ago
- Yahoo
Does IGIC Pay a Special Dividend?
International General Insurance Holdings Ltd. (NASDAQ:IGIC) is included among the 14 Stocks that Paid Special Dividends in 2025. An engineer wearing protective equipment, inspecting a large construction project. International General Insurance Holdings Ltd. (NASDAQ:IGIC) is a specialty insurance provider that offers coverage for both long-tail and short-tail risks, along with reinsurance services. By focusing on niche and complex markets with limited competition, IGI is able to maintain a strong position in underwriting. The company follows a careful and disciplined risk selection strategy, which has consistently led to performance that exceeds industry standards. Its combined ratio has remained well under 100%, supporting sustained profitability over the long term. In March, International General Insurance Holdings Ltd. (NASDAQ:IGIC) declared a special dividend of $0.025 per share, in addition to the company's regular dividend. On May 15, the company declared a 100% hike in its quarterly dividend to $0.05 per share. It remained committed to its shareholder obligation, returning $43.5 million to investors through regular and supplemental dividends in the first quarter of 2025. International General Insurance Holdings Ltd. (NASDAQ:IGIC) has a dividend yield of 0.83%, as recorded on July 23. While we acknowledge the potential of IGIC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
